<p>Supplement 1: The most commonly used DDI screening electronic databases</p><p>Database Properties Electronic system which provides the information for interacting drug </p><p> pairs with severity rating and referenced literature. For each </p><p> potentially interacting combination it provides information on clinical </p><p> outcomes or adverse reactions and latency period as well as possible Micromedex DrugReax® mechanism. The provided information is drug-specific rather than (http://www.micromedex.com) class-specific. The program classifies the potential DDIs into 4 </p><p> categories: »contraindicated«, »major«, »moderate« and »minor«. The </p><p> grade of documentation gives information about the quality of the </p><p> available data and ranges from »excellent« to »unlikely«. [12–14] The software classifies DDIs by the level of severity and the level of </p><p> scientific evidence. Potential DDIs were classified as »major«, </p><p>Drug Interaction Facts® »moderate« and »minor« according to the clinical outcomes. The level</p><p>(http://www.factsandcomparisons.com of scientific evidence of a potential DDI was classified on a five-point </p><p>) documentation scale, meaning potential DDI was supported by well-</p><p> controlled human studies in level 1 to level 5 where documentation of </p><p> potential DDI is poor or only theoretical. [29] Software classifies potential DDIs into 5 categories from A to X where</p><p>A represents »no known interaction«, B »no action needed«, C </p><p>»monitor therapy«, D »consider therapy modification« and X »avoid Lexi-Interact® combination or contraindication«. All the information is supported by (http://www.lexi.com) referenced literature and its level of scientific evidence. The software </p><p> provides the clinical outcome of the potential DDI and the </p><p> management. [3,31] Pharmavista The drug interaction program originates from the “ABDADatenbank”</p><p>(http://www.pharmavista.ch) published by the “Bundesvereinigung Deutscher Apothekerverbände” </p><p>(Federal Organization of the German Pharmacist Associations). For </p><p> each interacting drug combination, Pharmavista provides information </p><p> on the possible ADR, the clinical management and the mechanism of the pDDI, and provides literature references regarding the pDDI.</p><p>The program classifies severities of pDDIs into five categories: major, </p><p> moderate, minor, insignificant, and unidentified source. [3,33] A freely available online medical decision support tool which screens </p><p> for potential DDIs and classifies them according to mechanism as </p><p>Epocrates Rx® pharmacokinetic, pharmacodynamic or unknown. Potential DDIs are </p><p>(http://www.epocrates.com) classified into categories by management strategy as »contra-</p><p> indicated«, »avoid combination/use alternative«, »modify </p><p> treatment/monitor« and »caution«. [34] Electronic database which features detailed comments on more than </p><p>20000 drug interactions involving about 2000 specific substances. It </p><p>MediQ classifies the potential DDIs according to severity into 4 categories. It </p><p> also provides free texts for each DDI and phamacokinetic and </p><p> pharmacodynamic effects. [35] The software is available on internet and provides classification Drug Interaction Checker according to severity of potential DDIs into 3 categories: major, (http://www.drugs.com) moderate and minor. [36]</p>